DorsaVi

The future outlook for DorsaVi is defined by two converging growth drivers: the commercial scaling of its US clinical sensor business and the progressive development of its semiconductor IP portfolio. On the sensor side, the ATI Physical Therapy partnership provides a significant and scalable near-term revenue pathway. With more than 1,900 US clinical sites, the rollout of DorsaVi’s wearable technology across this network represents a meaningful commercial opportunity as adoption deepens and clinical use cases are validated. This existing revenue stream also helps fund the longer-dated semiconductor development program, providing an important degree of financial stability not typically seen in early-stage deep tech companies. On the semiconductor side, DorsaVi’s ReRAM and neuromorphic PIM IP position the company at the forefront of two of the fastest-growing areas of technology. ReRAM offers significant advantages over conventional flash memory – including higher energy efficiency, faster read/write performance, and superior endurance – attributes increasingly critical as AI workloads and data volumes expand globally. The neuromorphic PIM technology goes a step further, integrating computation directly within the memory layer. This architecture enables chips to “sense, think, and act” without relying on external cloud processing, reducing latency, power consumption, and thermal load – characteristics that are directly aligned with what next-generation robotics platforms will require. Pitt Street Research has set a sum-of-the-parts valuation target of A$0.22 per share – A$0.13 per share attributed to the Sensor business and A$0.09 per share to the ReRAM business. Key share price catalysts include the ReRAM tape-out milestone targeted for the second half of 2026, new semiconductor partnerships or licensing agreements, and additional commercial sensor contracts. The global neuromorphic computing market is forecast to grow from US$5.3bn in 2023 to more than US$20bn by 2030, placing DorsaVi in a high-growth sector at a very early stage of development.